This federal Project Grant award for $853,135 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant will fund research at Dignity Health's St. Joseph's Hospital and Medical Center in Phoenix, AZ to study the role of the complement C3A receptor in exacerbating brain injury and functional impairment following ischemic stroke. The research aims to 1) demonstrate that genetic inhibition of the C3A receptor on endothelial cells protects the blood-brain barrier, reduces inflammatory cell infiltration, and provides neuroprotection after stroke, 2) show that C3A receptor deletion protects against the detrimental effects of delayed tissue plasminogen activator (tPA) administration post-stroke, and 3) elucidate how C3A receptor-mediated synapse elimination contributes to long-term neurological dysfunction. This 5-year project is expected to provide a foundation for translating therapies targeting complement activation into clinical stroke treatments.
Generated 7/1/25, 5:17 AM